Non Patent Literature 5: Japanese Journal of Clinical Psychopharmacology, 2011, Vol. 14, No. 7, pp. 1123-1129

Non Patent Literature 6: Japanese Journal of Clinical Psychopharmacology, 2012, Vol. 15, No. 3, pp. 311-321

Summary

[0005a]

In one aspect, the present disclosure refers to an agent for preventing or treating brain atrophy, comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient.

[0005b]

In another aspect, the present disclosure refers to a use of an agent comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient in the manufacture of a medicament for preventing or treating brain atrophy.

Problem to be Solved by the Invention

[0006]

Drugs which prevent progress of AD by inhibiting neurodegeneration need to be developed early. An object of the present invention is to provide a drug which prevents progress of AD and a method of preventing progress of AD.

Means for Solving Problem

[0007]

In such circumstances, the present inventors have found that Compound A or a salt thereof has an effect of suppressing brain atrophy and have completed the present invention.

[0008]

The present invention provides the following.

(1) An agent for preventing or treating brain atrophy, comprising Compound A or a salt thereof as an active ingredient.

(2) The agent for preventing or treating brain atrophy according to (1), wherein the agent is is orally administered in a dose of 100 mg to 400 mg in terms of Compound A once a day.

(3) The agent for preventing or treating brain atrophy according to (1), wherein the agent is orally administered in a dose of 160 mg or 320 mg in terms of Compound A once a day.

(4) The agent for preventing or treating brain atrophy according to any one of (1) to (3), wherein the agent is for administration to a patient with a neurodegenerative disease.

CLAIMS

[Claim 1] An agent for preventing or treating brain atrophy, comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient.

[Claim 2] The agent for preventing or treating brain atrophy according to claim 1, wherein the agent is to be orally administered once a day in a dose of 100 mg to 400 mg in terms of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol per administration.

[Claim 3] The agent for preventing or treating brain atrophy according to claim 1, wherein the agent is to be orally administered once a day in a dose of 160 mg or 320 mg in terms of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol per administration.

[Claim 4] The agent for preventing or treating brain atrophy according to any one of claims 1 to 3, wherein the agent is for administration to a patient with a neurodegenerative disease.

[Claim 5] The agent for preventing or treating brain atrophy according to any one of claims 1 to 3, wherein the agent is for administration to a patient with Alzheimer's disease, Probable Alzheimer's disease, Possible Alzheimer's disease, Preclinical Alzheimer's disease, Prodromal Alzheimer's disease, mild cognitive impairment due to Alzheimer's disease (MCI due to AD) or mild cognitive impairment.

[Claim 6] The agent for preventing or treating brain atrophy according to any one of claims 1 to 3, wherein the agent is for administration to a patient with Alzheimer's disease, mild cognitive impairment due to Alzheimer's disease (MCI due to AD) or mild cognitive impairment.

[Claim 7] The agent for preventing or treating brain atrophy according to any one of claims 1 to 3, wherein the agent is for administration to a patient with Alzheimer's disease.

[Claim 8] The agent for preventing or treating brain atrophy according to any one of claims 1 to 3, wherein the agent is for administration to a patient with mild cognitive impairment due to Alzheimer's disease (MCI due to AD).

[Claim 9] Use of an agent comprising 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or a salt thereof as an active ingredient in the manufacture of a medicament for preventing or treating brain atrophy.

[Claim 10] The use according to claim 9, wherein the medicament is to be orally administered once a day in a dose of 100 mg to 400 mg in terms of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol per administration.

[Claim 11] The use according to claim 9, wherein the medicament is to be orally administered once a day in a dose of 160 mg or 320 mg in terms of 1- (3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol per administration.

[Claim 12] The use according to any one of claims 9 to 11, wherein the medicament is for administration to a patient with a neurodegenerative disease.

[Claim 13] The use according to any one of claims 9 to 11, wherein the medicament is for administration to a patient with Alzheimer's disease, Probable Alzheimer's disease, Possible Alzheimer's disease, Preclinical Alzheimer's disease, Prodromal Alzheimer's disease, mild cognitive impairment due to Alzheimer's disease (MCI due to AD) or mild cognitive impairment.

[Claim 14] The use according to any one of claims 9 to 11, wherein the medicament is for administration to a patient with Alzheimer's disease, mild cognitive impairment due to Alzheimer's disease (MCI due to AD) or mild cognitive impairment.

[Claim 15] The use according to any one of claims 9 to 11, wherein the medicament is for administration to a patient with Alzheimer's disease.

[Claim 16] The use according to any one of claims 9 to 11, wherein the medicament is for administration to a patient with mild cognitive impairment due to Alzheimer's disease (MCI due to AD).